[theold]

Valneva Reports Nine-Month 2021 Revenue and Cash

Inactivated COVID-19 Vaccine Candidate VLA2001

Positive pivotal Phase 3 Results reported
Superiority in terms of neutralizing antibody titer levels compared to comparator vaccine, AstraZeneca’s AZD1222
Non-inferiority in terms of seroconversion rates
Significantly better tolerability profile than comparator
Advance Purchase Agreement approved by European Commission (EC) for up to
60 million doses

https://www.globenewswire.com/news-relea...-Cash.html